Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells.

BACKGROUND Dialysis patients have accelerated atherosclerosis, with extensive calcification of both the intima and media. Cross-sectional studies have implicated hyperphosphatemia in this process, but the mechanism is unclear. METHODS To test the hypothesis that hyperphosphatemia and/or uremia induces vascular calcification, bovine vascular smooth muscle cells (BVSMC) were treated with increasing concentrations of beta-glycerophosphate, a phosphate donor, in the presence or absence of inhibitors for sodium/phosphate (Na/Pi) co-transport (foscarnet) or alkaline phosphatase (levamisole) for 48 hours. BVSMC also were incubated for various times with DMEM plus 15% pooled uremic sera from patients with low (LP) or high serum phosphorus (HP), or from pooled healthy control serum. Calcification in BVSMC was examined by quantitation of calcium deposition. Osteopontin expression and alkaline phosphatase activity were assessed by Western blotting and a colorimetric assay. RESULTS beta-glycerophosphate increased osteopontin expression and alkaline phosphatase activity in BVSMC. Inhibition of either alkaline phosphatase activity or Na/Pi co-transport abolished this effect. Compared to incubation with control human serum, BVSMC cultured with uremic sera had increased mineral deposition. Uremic sera also increased alkaline phosphatase activity and osteopontin expression in BVSMC. The addition of beta-glycerophosphate to uremic HP or LP sera did not further augment osteopontin expression. Blocking Na/Pi co-transport or alkaline phosphatase activity only partially inhibited uremic sera-induced osteopontin expression, indicating that other non-Na/Pi co-transport dependent mechanisms also are involved. CONCLUSION beta-glycerophosphate and uremic sera induce calcification and osteopontin expression in BVSMC. The uremic sera-induced osteopontin expression in BVSMC is partially mediated through alkaline phosphatase activity and a Na/Pi co-transporter dependent mechanism. However, other non-Na/Pi dependent mechanisms also contribute to accelerated vascular calcification in patients with ESRD.

[1]  O. H. Lowry,et al.  A method for the rapid determination of alkaline phosphates with five cubic millimeters of serum. , 1946, The Journal of biological chemistry.

[2]  R. Ross.  The smooth muscle cell. II. Growth of smooth muscle in culture and formation of elastic fibers. , 1971 .

[3]  H. Zollner,et al.  Handbook of Enzyme Inhibitors , 1989 .

[4]  J. Aubin,et al.  Initiation and progression of mineralization of bone nodules formed in vitro: the role of alkaline phosphatase and organic phosphate. , 1991, Bone and mineral.

[5]  K. Watson,et al.  Bone morphogenetic protein expression in human atherosclerotic lesions. , 1993, The Journal of clinical investigation.

[6]  M. Whyte.  Hypophosphatasia and the role of alkaline phosphatase in skeletal mineralization. , 1994, Endocrine reviews.

[7]  S. Schwartz,et al.  Osteopontin Expression in Cardiovascular Diseases a , 1995, Annals of the New York Academy of Sciences.

[8]  H. Koyama,et al.  β-Glycerophosphate Accelerates Calcification in Cultured Bovine Vascular Smooth Muscle Cells , 1995 .

[9]  M. Loghman-Adham,et al.  Use of phosphonocarboxylic acids as inhibitors of sodium-phosphate cotransport. , 1996, General pharmacology.

[10]  E. Zeitler,et al.  Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[11]  G. Karsenty,et al.  Osf2/Cbfa1: A Transcriptional Activator of Osteoblast Differentiation , 1997, Cell.

[12]  J. Aubin,et al.  Advances in the osteoblast lineage. , 1998, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[13]  R. Foley,et al.  Clinical epidemiology of cardiovascular disease in chronic renal disease. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[14]  H. Hilfiker,et al.  Cellular/molecular control of renal Na/Pi-cotransport. , 1998, Kidney international. Supplement.

[15]  G. Hill,et al.  Ischemic renal diseases: new insights into old entities. , 1998, Kidney international.

[16]  K. Watson,et al.  Fibronectin and collagen I matrixes promote calcification of vascular cells in vitro, whereas collagen IV matrix is inhibitory. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[17]  F. Port,et al.  Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[18]  C. Giachelli,et al.  Ectopic calcification: gathering hard facts about soft tissue mineralization. , 1999, The American journal of pathology.

[19]  P. Weissberg,et al.  Medial localization of mineralization-regulating proteins in association with Mönckeberg's sclerosis: evidence for smooth muscle cell-mediated vascular calcification. , 1999, Circulation.

[20]  M D McKee,et al.  Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin. , 1999, Circulation research.

[21]  H. Otani,et al.  Factors associated with calcification of the abdominal aorta in hemodialysis patients. , 1999, Kidney international. Supplement.

[22]  G. London,et al.  Association of hyperphosphataemia with haemodynamic disturbances in end-stage renal disease. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[23]  E. Moran,et al.  Phosphate is a specific signal for induction of osteopontin gene expression. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[24]  P. Weissberg,et al.  Expression of mineralisation-regulating proteins in association with human vascular calcification , 2000, Zeitschrift für Kardiologie.

[25]  C. Giachelli,et al.  Phosphorylation of Osteopontin Is Required for Inhibition of Vascular Smooth Muscle Cell Calcification* , 2000, The Journal of Biological Chemistry.

[26]  G. London,et al.  Arterial stiffening and vascular calcifications in end-stage renal disease. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[27]  R. Elashoff,et al.  Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. , 2000, The New England journal of medicine.

[28]  M. Rocco,et al.  Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. , 2000, Kidney international.

[29]  F. Port,et al.  Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[30]  A. Nicolaides,et al.  Investigation of chronic venous insufficiency: A consensus statement (France, March 5-9, 1997). , 2000, Circulation.

[31]  M. McKee,et al.  Phosphate regulation of vascular smooth muscle cell calcification. , 2000, Circulation research.

[32]  V F Froelicher,et al.  American College of Cardiology/American Heart Association Expert Consensus Document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. , 2000, Journal of the American College of Cardiology.

[33]  L. Demer,et al.  Regulatory mechanisms in vascular calcification. , 2000, Critical reviews in eukaryotic gene expression.

[34]  P. Weissberg,et al.  Vascular and valvar calcification: recent advances , 2001, Heart.

[35]  A. Evan,et al.  Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[36]  Sharon M Moe,et al.  Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. , 2002, Kidney international.